Senate Majority Leader Mitch McConnell (R-KY) said Congress’ priorities will switch from repealing Obamacare to focusing on drug prices, an area where both parties and President Donald Trump have common ground. (Bloomberg) House Minority Leader Nancy Pelosi (D-CA) also said in an interview that she would consider working with the president on the issue. (The Hill)

AbbVie has been accused of using a “patent thicket” to delay biosimilars to its Humira rheumatoid arthritis treatment. Mylan, Novartis, and Amgen have agreed to not license their biosimilar before 2023, but Boehringer Ingelheim has not signed the same agreement. Boehringer Ingelheim has filed court documents in attempts to prove AbbVie is at fault. (STAT)

AstraZeneca’s CEO said the company is entering a period of “sustained growth.” Although revenue fell by 14% in Q3, sales increased by 9% year-over-year due to its three cancer drugs Lynparza, Tagrisso, and Imfinzi. He credited the company’s commercial execution, new medicines, and success in emerging markets. (Endpoints)

The Trump administration issued final versions of two rules allowing exemptions for birth control coverage. The rules allow employers to deny coverage on religious or moral grounds. There are two lawsuits filed over these rules, one in California and one in Pennsylvania. (Washington Post)

MM&M asked experts to predict what the next two years could hold for pharma- and healthcare-related legislation. Here’s what experts from PhRMA, Avalere, the Coalition for Healthcare Communications, and APCO Worldwide had to say. (MM&M)